A French Real-life Study: EvaluatioN of durvALumab utilization and effectiveness for first line extensive stage small cell lung cancer.

Trial Identifier: D419QR00014
Sponsor: AstraZeneca
Collaborator:
Kappa Santé
Start Date: November 2022
Primary Completion Date: March 2027
Study Completion Date: March 2027
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
France ANGERS, France, 49933
France Argenteuil, France, 95107
France Avignon, France, 84000
France Avignon, France, 84918
France Bayonne, France, 64100
France Bordeaux Cedex, France, 33077
France Clermont-Ferrand, France, 63000
France Créteil, France, 94000
France DIJON, France, 21000
France Epagny Metz-Tessy, France, 74370
France Évreux, France, 27015
France Gleize, France, 69400
France La Roche sur Yon, France, 85925
France La Rochelle, France, 17000
France Le Chesnay-Rocquencourt, France, 78150
France Limoges, France, 87000
France Marseille, France, 13008
France Nancy, France, 54100
France Nimes, France, 30000
France Nîmes, France, 30900
France OSNY, France, 95520
France Paris, France, 75005
France Pau, France, 64000
France RENNES, France
France Rouen, France, 76000
France Saint Gregoire, France, 35760
France Saint-Etienne, France, 42100
France Saint-Quentin, France, 2321
France Toulon, France, 83000
France Toulouse, France, 31400
France TOULOUSE, France, 31076
France Valenciennes, France, 59300
France VANNES, France, 56017
France VILLEURBANNE, France, 69100